Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Novel PARP Inhibitor–Based Combinations Targeting Improved Patient Outcomes in Prostate Cancer
  • CME

Charles J. Ryan, MD
Released: April 12, 2021
Back Next

References

  1. Friedlander TW, Pritchard CC, Beltran H. Personalizing therapy for metastatic prostate cancer: the role of solid and liquid tumor biopsies. Am Soc Clin Oncol Educ Book. 2017;37:358-369.
  2. Robinson D, Van Allen EM, Wu Y-M, et al. Integrative clinical genomics of advanced prostate cancer. Cell. 2015;161:1215-1228.
  3. Pritchard CC, Mateo J, Walsh MF, et al. Inherited DNA-repair gene mutations in men with metastatic prostate cancer. N Engl J Med. 2016;375:443-453.

  4. Olaparib [prescribing information]. Cambridge, UK: AstraZeneca; 2020.
  5. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
  6. ClinicalTrials.gov. Study of olaparib (Lynparza™) versus enzalutamide or abiraterone acetate in men with metastatic castration-resistant prostate cancer (PROfound Study). clinicaltrials.gov/ct2/show/NCT02987543. Accessed March 30, 2021.
  7. Hussain M, Mateo J, Fizazi K, et al. Survival with olaparib in metastatic castration-resistant prostate cancer. N Engl J Med. 2020; 383:2345-2357.
  8. Rucaparib [prescribing information]. Boulder, CO: Clovis Oncology; 2020.
  9. Abida W, Patnaik A, Campbell D, et al. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J Clin Oncol. 2020; 38:3763-3772.
  10. ClinicalTrials.gov. A study of rucaparib in patients with metastatic castration-resistant prostate cancer and homologous recombination gene deficiency (TRITON2). clinicaltrials.gov/ct2/show/NCT02952534. Accessed March 30, 2021.
  11. Ryan CJ, Abida W, Bryce AH, et al. TRITON3: An international, randomized, open-label, phase III study of the PARP inhibitor rucaparib vs. physician’s choice of therapy for patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD). Presented at: 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 8-10, 2018. Abstract TPS389.
  12. ClinicalTrials.gov. A study of rucaparib versus physician's choice of therapy in patients with metastatic castration-resistant prostate cancer and homologous recombination gene deficiency (TRITON3). clinicaltrials.gov/ct2/show/NCT02975934. Accessed March 30, 2021.
  13. de Bono JS, Mehra N, Higano CS, et al. TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 93.
  14. ClinicalTrials.gov. A study of talazoparib in men with dna repair defects and metastatic castration-resistant prostate cancer. clinicaltrials.gov/ct2/show/NCT03148795. Accessed March 30, 2021.
  15. Abida W, Bryce AH, Vogelzang NJ, et al. Preliminary results from TRITON2: a phase 2 study of rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination repair (HRR) gene alterations. Presented at: 2018 European Society for Medical Oncology Congress. October 19-23, 2018. Abstract 3619.
  16. Lozano Mejorada R, Castro Marcos E, Aragon IM, et al. Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR-A study. Presented at: 2020 European Society for Medical Oncology Virtual Congress; September 19-21, 2020. Abstract 612MO.
  17. Hussain M, Daignault-Newton S, Twardowski PW, et al. Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012. J Clin Oncol. 2018;36:991-999.
  18. Polkinghorn WR, Parker JS, Lee MX, et al. Androgen receptor signaling regulates DNA repair in prostate cancers. Cancer Discov. 2013;3:1245-1253.
  19. Schiewer MJ, Goodwin JF, Han S, et al. Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov. 2012;2:1134-1149.
  20. Asim M, Tarish F, Zecchini HI, et al. Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. Nat Commun. 2017;8:374.
  21. Clarke N, Wiechno P, Alekseev B, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2018;19:975-986.
  22. ClinicalTrials.gov. Ph II study to evaluate olaparib with abiraterone in treating metastatic castration resistant prostate cancer. clinicaltrials.gov/ct2/show/NCT01972217. Accessed March 30, 2021.
  23. ClinicalTrials.gov. Study on olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer. clinicaltrials.gov/ct2/show/NCT03732820. Accessed March 30, 2021.
  24. Agarwal N, Shore ND, Dunshee C, et al. TALAPRO-2: a placebo-controlled phase III study of talazoparib (TALA) plus enzalutamide (ENZA) for patients with first-line metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2020 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract TPS5598.
  25. ClinicalTrials.gov. Talazoparib + enzalutamide vs. enzalutamide monotherapy in mCRPC (TALAPRO-2). clinicaltrials.gov/ct2/show/NCT03395197. Accessed March 30, 2021.
  26. ClinicalTrials.gov. A clinical study evaluating the benefit of adding rucaparib to enzalutamide for men with metastatic prostate cancer that has become resistant to testosterone-deprivation therapy (CASPAR). clinicaltrials.gov/ct2/show/NCT04455750. Accessed March 30, 2021.
  27. Rao A, Morris D, Assikis VJ, et al. Rucaparib plus enzalutamide in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Pharmacokinetics (PK) and safety data from the phase Ib RAMP study. Presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 79.
  28. ClinicalTrials.gov. Study of oral rucaparib with other anticancer agents in metastatic castration resistant prostate cancer patients (RAMP). clinicaltrials.gov/ct2/show/NCT04179396. Accessed March 30, 2021.
  29. Chi KN, Rathkopf DE, Attard G, et al. A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (MAGNITUDE). Presented at: 2020 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract TPS5588.
  30. ClinicalTrials.gov. A study of niraparib in combination with abiraterone acetate and prednisone versus abiraterone acetate and prednisone for treatment of participants with metastatic prostate cancer (MAGNITUDE). clinicaltrials.gov/ct2/show/NCT03748641. Accessed March 30, 2021.
  31. Vikas P, Borcherding N, Chennamadhavuni A, et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol. 2020;10:570.
  32. Yu EY, Rodriguez JMMP, Gravis G, et al. Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results. Presented at: 2020 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract 5544.
  33. Arranz Arija JA, Yu EY, Piulats JM, et al. Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update. Presented at: 2020 European Society for Medical Oncology Virtual Congress; September 19-21, 2020. Abstract 621P.
  34. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) combination therapies in metastatic castration-resistant prostate cancer (MK-3475-365/KEYNOTE-365). clinicaltrials.gov/ct2/show/NCT02861573. Accessed March 30, 2021.
  35. ClinicalTrials.gov. Study of pembrolizumab (MK-3475) plus olaparib versus abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) (MK-7339-010/KEYLYNK-010) (KEYLYNK-010 clinicaltrials.gov/ct2/show/NCT03834519. Accessed March 30, 2021.
  36. ClinicalTrials.gov. An investigational immunotherapy study of nivolumab in combination with rucaparib, docetaxel, or enzalutamide in metastatic castration-resistant prostate cancer (CheckMate 9KD). clinicaltrials.gov/ct2/show/NCT03338790. Accessed March 30, 2021.
  37. Alter R, Fleming GF, Stadler WM, et al. A phase Ib/IIa study of rucaparib (PARP inhibitor) combined with nivolumab in metastatic castrate-resistant prostate cancer and advanced/recurrent endometrial cancer. Presented at: 2019 American Society of Clinical Oncology Annual Meeting; May 31-June 4, 2019. Abstract TPS2663.
  38. ClinicalTrials.gov. Rucaparib and nivolumab in patients with prostate or endometrial cancer. clinicaltrials.gov/ct2/show/NCT03572478. Accessed March 30, 2021.
  39. Karzai F, VanderWeele D, Madan RA, et al. Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutations. J Immunother Cancer. 2018;6:141.
  40. ClinicalTrials.gov. Phase I/II study of the anti-programmed death ligand-1 antibody MEDI4736 in combination with olaparib and/or cediranib for advanced solid tumors and advanced or recurrent ovarian, triple negative breast, lung, prostate and colorectal cancers. clinicaltrials.gov/ct2/show/NCT02484404. Accessed March 30, 2021.
  41. Schwarzenbach H, Gahan PB. Resistance to cis- and carboplatin initiated by epigenetic changes in ovarian cancer patients. Cancer Drug Resist. 2019;2:271-296.
  42. Schmid S, Omlin A, Higano C, et al. Activity of platinum-based chemotherapy in patients with advanced prostate cancer with and without DNA repair gene aberrations. JAMA Netw Open. 2020;3:e2021692.
  43. ClinicalTrials.gov. Docetaxel, carboplatin, and rucaparib camsylate in treating patients with metastatic castration resistant prostate cancer with homologous recombination DNA repair deficiency. clinicaltrials.gov/ct2/show/NCT03442556. Accessed March 30, 2021.
  44. Kelly WK, Leiby B, Einstein DJ, et al. Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo). Presented at: 2020 American Society of Clinical Oncology Annual Meeting; May 29-31, 2020. Abstract 5540.
  45. ClinicalTrials.gov. Phase IB trial of radium-223 and niraparib in patients with castrate resistant prostate cancer (NiraRad). clinicaltrials.gov/ct2/show/NCT03076203. Accessed March 30, 2021.
  46. Kaplan AR, Gueble S, Liu Y, et al. Cediranib suppresses homology-directed DNA repair through down-regulation of BRCA1/2 and RAD51. Sci Transl Med. 2019;11:eaav4508.
  47. Liu JF, Barry WT, Birrer M, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019;30:551-557.
  48. McKay RR, Radke MR, Shyr Y, et al. Biomarker analysis from a randomized phase II study of olaparib with or without cediranib in men with metastatic castration-resistant prostate cancer (mCRPC). Presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11-13, 2021. Abstract 7.
  49. ClinicalTrials.gov. Olaparib with or without cediranib in treating patients with metastatic castration-resistant prostate cancer. clinicaltrials.gov/ct2/show/NCT02893917. Accessed March 30, 2021.
  50. ClinicalTrials.gov. Niraparib with standard combination radiation therapy and androgen deprivation therapy in treating patients with high risk prostate cancer (NADIR). clinicaltrials.gov/ct2/show/NCT04037254. Accessed March 30, 2021.
Back Next
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Pfizer, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue